|
1
|
Kipps E, Tan DSP and Kaye SB: Meeting the
challenge of ascites in ovarian cancer: New avenues for therapy and
research. Nat Rev Cancer. 13:273–282. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Psallidas I, Kalomenidis I, Porcel JM,
Robinson BW and Stathopoulos GT: Malignant pleural effusion: From
bench to bedside. Eur Respir Rev. 25:189–198. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Egan AM, McPhillips D, Sarkar S and Breen
DP: Malignant pleural effusion. QJM. 107:179–184. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mikuła-Pietrasik J, Uruski P, Szubert S,
Moszyński R, Szpurek D, Sajdak S, Tykarski A and Książek K:
Biochemical composition of malignant ascites determines high
aggressiveness of undifferentiated ovarian tumors. Med Oncol.
33(94)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yin T, Wang G, He S, Shen G, Su C, Zhang
Y, Wei X, Ye T, Li L, Yang S, et al: Malignant pleural effusion and
ascites induce epithelial-mesenchymal transition and cancer
stem-like cell properties via the vascular endothelial growth
factor (VEGF)/Phosphatidylinositol 3-kinase (PI3K)/Akt/mechanistic
target of rapamycin (mTOR) pathway. J Biol Chem. 291:26750–26761.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wu DW, Chang WA, Liu KT, Yen MC and Kuo
PL: Vascular endothelial growth factor and protein level in pleural
effusion for differentiating malignant from benign pleural
effusion. Oncol Lett. 14:3657–3662. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chudecka-Glaz A, Cymbaluk-Płoska A,
Menkiszak J, Pius-Sadowska E, Machaliński B, Sompolska-Rzechuła A
and Rzepka-Górska I: Assessment of selected cytokines, proteins,
and growth factors in the peritoneal fluid of patients
with ovarian cancer and benign gynecological conditions. Onco
Targets Ther. 8:471–485. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kucukgoz Gulec U, Paydas S, Guzel AB,
Buyukkurt S, Seydaoglu G and Vardar MA: Comparative analysis of CA
125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in
serum and peritoneal fluid in patients with ovarian neoplasia. Med
Oncol. 29:2937–2943. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cheng D, Liang B and Kong H: Clinical
significance of vascular endothelial growth factor and endostatin
levels in the differential diagnosis of malignant and benign
ascites. Med Oncol. 29:1397–1402. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Matte I, Lane D, Laplante C, Rancourt C
and Piché A: Profiling of cytokines in human epithelial ovarian
cancer ascites. Am J Cancer Res. 2:566–580. 2012.PubMed/NCBI
|
|
11
|
Kolomeyevskaya N, Eng KH, Khan ANH,
Grzankowski KS, Singel KL, Moysich K and Segal BH: Cytokine
profiling of ascites at primary surgery identifies an interaction
of tumor necrosis factor-α and interleukin-6 in predicting reduced
progression-free survival in epithelial ovarian cancer. Gynecol
Oncol. 138:352–357. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Saraya T, Ohkuma K, Watanabe T, Mikura S,
Kobayashi F, Aso J, Nunokawa H, Honda K, Ogawa Y, Tamura M, et al:
Diagnostic value of vascular endothelial growth factor,
transforming growth factor-β, Interleukin-8, and the ratio of
lactate dehydrogenase to adenosine deaminase in pleural effusion.
Lung. 196:249–254. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
van Hensbergen Y, Broxterman HJ,
Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM and
Hoekman K: Soluble aminopeptidase N/CD13 in malignant and
nonmalignant effusions and intratumoral fluid. Clin Cancer Res.
8:3747–3754. 2002.PubMed/NCBI
|
|
14
|
Fiorelli A, Ricci S, Feola A, Mazzella A,
D'Angelo L, Santini M, Di Domenico M and Di Carlo A: Matrix
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in
diagnosis of pleural effusion of malignant origin. Interact
Cardiovasc Thorac Surg. 22:411–418. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Palacios-Corona R, Ortı́z-Navarrete VF,
Said-Fernández S, Rodrı́guez-Padilla C and González-Garza MT:
Detection of a factor released by L5178Y lymphoblasts that inhibits
mouse macrophage-activation induced by lipopolysaccharides. Arch
Med Res. 30:298–302. 1999.PubMed/NCBI View Article : Google Scholar
|
|
16
|
González-Garza MT, Palacios-Corona R,
Ortiz-Navarrete V, Castro-Garza J and Said-Fernandez S: The
macrophage-activation inhibitory factor (MAIF) from L5178Y murine
lymphoma favors experimental amebic hepatic abscess development in
Balb/c mice. Arch Med Res. 31 (Suppl 4):S104–S105. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Palacios-Corona R, Ortiz-Navarrete V,
Castro-Garza J, Said-Fernandez S, Moreno-Cuevas J, Guzmán-Delgado N
and González-Garza MT: Macrophage-activation inhibitor factor from
L5178Y murine lymphoma and formation of hepatic abscesses in BALB/c
Mice. Arch Med Res. 37:474–478. 2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cohen M, Pierredon S, Wuillemin C, Delie F
and Petignat P: Acellular fraction of ovarian cancer ascites induce
apoptosis by activating JNK and inducing BRCA1, Fas and FasL
expression in ovarian cancer cells. Oncoscience. 1:262–271.
2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Richardson M, Gunawan J, Hatton MWC,
Seidlitz E, Hirte HW and Singh G: Malignant ascites fluid (MAF),
including ovarian-cancer-associated MAF, contains angiostatin and
other factor(s) which inhibit angiogenesis. Gynecol Oncol.
86:279–287. 2002.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ruiz E, Alemán C, Alegre J, Monasterio J,
Segura RM, Armadans L, Vázquez A, Soriano T and Fernández de
Sevilla T: Angiogenic factors and angiogenesis inhibitors in
exudative pleural effusions. Lung. 183:185–195. 2005.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jandu N, Richardson M, Singh G, Hirte H
and Hatton MW: Human ovarian cancer ascites fluid contains a
mixture of incompletely degraded soluble products of fibrin that
collectively possess an antiangiogenic property. Int J Gynecol
Cancer. 16:1536–1544. 2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Puiffe ML, Le Page C, Filali-Mouhim A,
Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM and
Mes-Masson AM: Characterization of ovarian cancer ascites on cell
invasion, proliferation, spheroid formation, gene expression in an
in vitro model of epithelial ovarian cancer. Neoplasia. 9:820–829.
2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Flannagan R, Heit B and Heinrichs D:
Antimicrobial mechanisms of macrophages and the immune evasion
strategies of staphylococcus aureus. Pathogens. 4:826–868.
2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lam GY, Huang J and Brumell JH: The many
roles of NOX2 NADPH oxidase-derived ROS in immunity. Semin
Immunopathol. 32:415–30. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shapouri-Moghaddam A, Mohammadian S,
Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi
A, Afshari JT and Sahebkar A: Macrophage plasticity, polarization,
and function in health and disease. J Cell Physiol. 233:6425–6440.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Piché A: Malignant peritoneal effusion
acting as a tumor environment in ovarian cancer progression: Impact
and significance. World J Clin Oncol. 9:167–171. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bal-Price A, Gartlon J and Brown GC:
Nitric oxide stimulates PC12 cell proliferation via cGMP and
inhibits at higher concentrations mainly via energy depletion.
Nitric Oxide. 14:238–246. 2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Villalobo A: Nitric oxide and cell
proliferation. FEBS J. 273:2329–2344. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Keshet R and Erez A: Arginine and the
metabolic regulation of nitric oxide synthesis in cancer. Dis Model
Mech. 11(dmm033332)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cheng H, Wang L, Mollica M, Re AT, Wu S
and Zuo L: Nitric oxide in cancer metastasis. Cancer Lett. 353:1–7.
2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lat T and Paul M: Malignant Effusion. In:
StatPearls. Treasure Island (FL). https://www.ncbi.nlm.nih.gov/books/NBK519522/ Accessed
July 19, 2020.
|
|
33
|
Soini Y, Kahlos K, Puhakka A, Lakari E,
Säily M, Pääkkö P and Kinnula V: Expression of inducible nitric
oxide synthase in healthy pleura and in malignant mesothelioma. Br
J Cancer. 83:880–886. 2000.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Li Y, Lian H, Jia Q and Wan Y: Proteome
screening of pleural effusions identifies IL1A as a diagnostic
biomarker for non-small cell lung cancer. Biochem Biophys Res
Commun. 457:177–182. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li H, Tang Z, Zhu H, Ge H, Cui S and Jiang
W: Proteomic study of benign and malignant pleural effusion. J
Cancer Res Clin Oncol. 142:1191–1200. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jin J, Son M, Kim H, Kim H, Kong SH, Kim
HK, Kim Y and Han D: Comparative proteomic analysis of human
malignant ascitic fluids for the development of gastric cancer
biomarkers. Clin Biochem. 56:55–61. 2018.PubMed/NCBI View Article : Google Scholar
|
